The EPS projection of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for period quarter completed 2016-12-31 is $0.21.
The EPS estimates pronounced a week and 30 days ago were $0.21 and $0.21 correspondingly. The EPS forecasts specified 60 and 90 days before were $0.21 and $0.21 respectively. From a week ago, the aberration in EPS forecast is 0 percent.
The mean EPS prediction straightaway before the earnings release for the quarter completed 2 is $0.21 based on 6 EPS estimations. The EPS stated on 2016-08-02 was $0.18. The EPS surprise was $0.05, or 38.46 percent. The standard deviation as per known EPS estimates was $0.02.
The positive EPS revisions were 0 a week earlier and negative revisions were 0. In last 30 and 60 days, the positive EPS revisions were 0 and 0 correspondingly, while for 90 and 120 days, revisions count was 2 and 2.
The negative revisions of per-share earnings in the last 30 and 60-days were 0 and 2 in that order. however, for 90 and 120 days’ period, the count was 3 and 3 in that order.
EPS revisions upgrade and downgrade in the last 18 days were 1 and 4 correspondingly.
Quarterly Sales Estimates
The arithmetic mean of probable annual sales of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is $58.922 and the median was $58.655. The estimate is stated by 4 analysts for the fiscal 2016.
The highest annual projection is $60.97 and lowest sales target is $57.41. This marks a standard deviation of $1.529.
Almost 4 have given revised positive sales forecast in the past week and 4 have downgraded forecasts. As per the stated estimates, the change in target from the past week is 0 percent.
Nearly 4 have revised sales projections in positive side over the past month and 4 have downgraded forecasts. This shows a mean estimate deviation of 0 percent.
Just about 4 have revised sales forecast on plus side over the quarter and 4 have downgraded forecasts. This shows mean estimate deviation of -1.162 percent.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...